Your browser doesn't support javascript.
loading
Epidemiology and pathophysiology of malignancy in common variable immunodeficiency?
Tak Manesh, A; Azizi, G; Heydari, A; Kiaee, F; Shaghaghi, M; Hossein-Khannazer, N; Yazdani, R; Abolhassani, H; Aghamohammadi, A.
Afiliación
  • Tak Manesh A; Member of RACGP, Melbourne, Australia.
  • Azizi G; Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Heydari A; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Kiaee F; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Shaghaghi M; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Hossein-Khannazer N; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Yazdani R; Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Abolhassani H; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Swe
  • Aghamohammadi A; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: aghamohammadi@tums.ac.ir.
Allergol Immunopathol (Madr) ; 45(6): 602-615, 2017.
Article en En | MEDLINE | ID: mdl-28411962
Common variable immunodeficiency (CVID) is a diagnostic category of primary immunodeficiency (PID) which may present with heterogeneous disorders including recurrent infections, autoimmunity, granulomatous diseases, lymphoid and other types of malignancies. Generally, the incidence of malignancy in CVID patients is around 1.5-20.7% and usually occurs during the 4th-6th decade of life. Non-Hodgkin lymphoma is the most frequent malignancy, followed by epithelial tumours of stomach, breast, bladder and cervix. The exact pathological mechanisms for cancer development in CVID are not fully determined; however, several mechanisms including impaired genetic stability, genetic predisposition, immune dysregulation, impaired clearance of oncogenic viruses and bacterial infections, and iatrogenic causes have been proposed to contribute to the high susceptibility of these patients to malignancies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunodeficiencia Variable Común / Sistema Inmunológico / Neoplasias Tipo de estudio: Incidence_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Allergol Immunopathol (Madr) Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Singapur

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunodeficiencia Variable Común / Sistema Inmunológico / Neoplasias Tipo de estudio: Incidence_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Allergol Immunopathol (Madr) Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Singapur